Adenoviral vector vaccine, and preparation method and use thereof

Abstract

Provided are a modified recombinant adenoviral vector, and a preparation method and use thereof. The modified adenoviral vector can reduce the negative charge level on the surface of adenovirus particles, so as to reduce interaction between the adenoviral vector and PF4 (platelet factor 4). By administering the modified adenovirus vector, the risk of thrombus can be reduced, vaccine safety and effectiveness are improved, and the vaccine is more suitable for high-risk crowds such as elder people, children and pregnant women. The recombinant adenovirus can be widely used for gene therapy, tumor immunization and/or antiviral vaccination, including the use of initiating a primary immune response in a human or mammal to initiate a reinforced immune response for destroying the tolerance of a host to an autoantigen. The modified recombinant adenovirus can be used for developing a mucosal administration formulation. Compared with injection, the mucosal administration formulation has compliance and also lower dosage, and can generate triple protection effects of humoral immunity, cellular immunity and mucosal immunity.

Dependencies are inferred from the claim text.